STOCK TITAN

[Form 4] Penumbra, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

iRhythm Technologies, Inc. (IRTC) – Form 4 Insider Transaction

On 23 June 2025, Chief Commercial Officer Chad Patterson sold 936 shares of IRTC common stock at $150.00 per share, generating gross proceeds of roughly $140,400. The sale was made pursuant to a Rule 10b5-1 trading plan that Patterson adopted on 25 November 2024, indicating the transaction was pre-scheduled and not necessarily the result of contemporaneous market sentiment.

After the sale, Patterson retains 48,929 shares, keeping a substantial equity stake in the company. No derivative securities were exercised or disposed, and there were no additional transactions disclosed in Table II.

  • The sale represents approximately 1.9 % of Patterson’s reported holdings, suggesting a modest portfolio rebalancing rather than a major reduction.
  • Use of a 10b5-1 plan enhances transparency and mitigates concerns about opportunistic trading.

iRhythm Technologies, Inc. (IRTC) – Transazione Insider Modulo 4

Il 23 giugno 2025, il Chief Commercial Officer Chad Patterson ha venduto 936 azioni di azioni ordinarie IRTC a $150,00 per azione, generando un ricavo lordo di circa $140.400. La vendita è stata effettuata in base a un piano di trading Rule 10b5-1 adottato da Patterson il 25 novembre 2024, indicando che la transazione era preprogrammata e non necessariamente frutto del sentiment di mercato contemporaneo.

Dopo la vendita, Patterson mantiene 48.929 azioni, conservando una partecipazione azionaria significativa nella società. Non sono stati esercitati o alienati titoli derivati e non sono state divulgate ulteriori transazioni nella Tabella II.

  • La vendita rappresenta circa il 1,9% delle partecipazioni dichiarate di Patterson, suggerendo un riequilibrio modesto del portafoglio più che una riduzione significativa.
  • L’utilizzo di un piano 10b5-1 aumenta la trasparenza e riduce i timori di operazioni speculative.

iRhythm Technologies, Inc. (IRTC) – Transacción Insider Formulario 4

El 23 de junio de 2025, el Director Comercial Chad Patterson vendió 936 acciones de acciones ordinarias de IRTC a $150.00 por acción, generando ingresos brutos de aproximadamente $140,400. La venta se realizó conforme a un plan de negociación Rule 10b5-1 que Patterson adoptó el 25 de noviembre de 2024, lo que indica que la transacción fue preprogramada y no necesariamente resultado del sentimiento de mercado contemporáneo.

Después de la venta, Patterson conserva 48,929 acciones, manteniendo una participación accionaria sustancial en la compañía. No se ejercieron ni dispusieron valores derivados, y no se divulgaron transacciones adicionales en la Tabla II.

  • La venta representa aproximadamente el 1.9% de las participaciones reportadas de Patterson, lo que sugiere un reequilibrio modesto de cartera más que una reducción importante.
  • El uso de un plan 10b5-1 mejora la transparencia y mitiga las preocupaciones sobre operaciones oportunistas.

iRhythm Technologies, Inc. (IRTC) – Form 4 내부자 거래

2025년 6월 23일, 최고 상업 책임자 Chad Patterson는 IRTC 보통주 936주를 주당 $150.00에 매도하여 약 $140,400의 총 수익을 올렸습니다. 이 매도는 Patterson이 2024년 11월 25일 채택한 Rule 10b5-1 거래 계획에 따라 이루어졌으며, 이는 거래가 사전에 예약된 것이며 반드시 동시 시장 심리의 결과는 아님을 나타냅니다.

매도 후 Patterson은 48,929주를 보유하며 회사에 상당한 지분을 유지하고 있습니다. 파생 증권의 행사나 처분은 없었고, 표 II에 추가 거래 내역도 공개되지 않았습니다.

  • 이번 매도는 Patterson이 보고한 보유 지분의 약 1.9%에 해당하며, 이는 대규모 감소보다는 소규모 포트폴리오 조정임을 시사합니다.
  • 10b5-1 계획의 사용은 투명성을 높이고 기회주의적 거래에 대한 우려를 완화합니다.

iRhythm Technologies, Inc. (IRTC) – Transaction d’initié Formulaire 4

Le 23 juin 2025, le Chief Commercial Officer Chad Patterson a vendu 936 actions ordinaires d’IRTC à 150,00 $ par action, générant un produit brut d’environ 140 400 $. La vente a été réalisée conformément à un plan de négociation Rule 10b5-1 adopté par Patterson le 25 novembre 2024, ce qui indique que la transaction était préprogrammée et pas nécessairement le résultat du sentiment du marché au moment.

Après la vente, Patterson détient 48 929 actions, conservant ainsi une participation importante dans la société. Aucun titre dérivé n’a été exercé ou cédé, et aucune autre transaction n’a été divulguée dans le Tableau II.

  • La vente représente environ 1,9 % des avoirs déclarés de Patterson, suggérant un rééquilibrage modéré du portefeuille plutôt qu’une réduction majeure.
  • L’utilisation d’un plan 10b5-1 améliore la transparence et atténue les inquiétudes concernant des opérations opportunistes.

iRhythm Technologies, Inc. (IRTC) – Insider-Transaktion Formular 4

Am 23. Juni 2025 verkaufte der Chief Commercial Officer Chad Patterson 936 Aktien der IRTC-Stammaktien zu je 150,00 $ und erzielte dadurch Bruttoerlöse von etwa 140.400 $. Der Verkauf erfolgte im Rahmen eines Rule 10b5-1 Handelsplans, den Patterson am 25. November 2024 eingeführt hatte, was darauf hinweist, dass die Transaktion vorab geplant war und nicht unbedingt auf aktuelle Marktstimmungen zurückzuführen ist.

Nach dem Verkauf hält Patterson weiterhin 48.929 Aktien und behält somit eine bedeutende Beteiligung am Unternehmen. Es wurden keine derivativen Wertpapiere ausgeübt oder veräußert, und es wurden keine weiteren Transaktionen in Tabelle II offengelegt.

  • Der Verkauf entspricht etwa 1,9 % von Pattersons gemeldeten Beständen und deutet eher auf eine moderate Portfolioanpassung als auf eine wesentliche Reduzierung hin.
  • Die Nutzung eines 10b5-1-Plans erhöht die Transparenz und verringert Bedenken hinsichtlich opportunistischer Handelsaktivitäten.
Positive
  • Sale executed under Rule 10b5-1, enhancing transparency and reducing concerns about timing.
  • Officer retains 48,929 shares, indicating continued confidence and alignment with shareholders.
Negative
  • Any insider sale can be perceived negatively by the market, even if modest in size.

Insights

TL;DR: Routine 936-share sale (~$140k) under 10b5-1 plan; minimal impact on insider’s 48.9k-share stake.

The filing shows a small, pre-planned disposition by the Chief Commercial Officer. At roughly 2 % of his holdings, the sale is unlikely to signal strategic unease. Continued ownership of nearly 49 k shares maintains alignment with shareholders. The 10b5-1 framework further reduces the interpretive risk typically associated with insider selling. Overall impact on valuation or sentiment should be neutral barring other catalysts.

iRhythm Technologies, Inc. (IRTC) – Transazione Insider Modulo 4

Il 23 giugno 2025, il Chief Commercial Officer Chad Patterson ha venduto 936 azioni di azioni ordinarie IRTC a $150,00 per azione, generando un ricavo lordo di circa $140.400. La vendita è stata effettuata in base a un piano di trading Rule 10b5-1 adottato da Patterson il 25 novembre 2024, indicando che la transazione era preprogrammata e non necessariamente frutto del sentiment di mercato contemporaneo.

Dopo la vendita, Patterson mantiene 48.929 azioni, conservando una partecipazione azionaria significativa nella società. Non sono stati esercitati o alienati titoli derivati e non sono state divulgate ulteriori transazioni nella Tabella II.

  • La vendita rappresenta circa il 1,9% delle partecipazioni dichiarate di Patterson, suggerendo un riequilibrio modesto del portafoglio più che una riduzione significativa.
  • L’utilizzo di un piano 10b5-1 aumenta la trasparenza e riduce i timori di operazioni speculative.

iRhythm Technologies, Inc. (IRTC) – Transacción Insider Formulario 4

El 23 de junio de 2025, el Director Comercial Chad Patterson vendió 936 acciones de acciones ordinarias de IRTC a $150.00 por acción, generando ingresos brutos de aproximadamente $140,400. La venta se realizó conforme a un plan de negociación Rule 10b5-1 que Patterson adoptó el 25 de noviembre de 2024, lo que indica que la transacción fue preprogramada y no necesariamente resultado del sentimiento de mercado contemporáneo.

Después de la venta, Patterson conserva 48,929 acciones, manteniendo una participación accionaria sustancial en la compañía. No se ejercieron ni dispusieron valores derivados, y no se divulgaron transacciones adicionales en la Tabla II.

  • La venta representa aproximadamente el 1.9% de las participaciones reportadas de Patterson, lo que sugiere un reequilibrio modesto de cartera más que una reducción importante.
  • El uso de un plan 10b5-1 mejora la transparencia y mitiga las preocupaciones sobre operaciones oportunistas.

iRhythm Technologies, Inc. (IRTC) – Form 4 내부자 거래

2025년 6월 23일, 최고 상업 책임자 Chad Patterson는 IRTC 보통주 936주를 주당 $150.00에 매도하여 약 $140,400의 총 수익을 올렸습니다. 이 매도는 Patterson이 2024년 11월 25일 채택한 Rule 10b5-1 거래 계획에 따라 이루어졌으며, 이는 거래가 사전에 예약된 것이며 반드시 동시 시장 심리의 결과는 아님을 나타냅니다.

매도 후 Patterson은 48,929주를 보유하며 회사에 상당한 지분을 유지하고 있습니다. 파생 증권의 행사나 처분은 없었고, 표 II에 추가 거래 내역도 공개되지 않았습니다.

  • 이번 매도는 Patterson이 보고한 보유 지분의 약 1.9%에 해당하며, 이는 대규모 감소보다는 소규모 포트폴리오 조정임을 시사합니다.
  • 10b5-1 계획의 사용은 투명성을 높이고 기회주의적 거래에 대한 우려를 완화합니다.

iRhythm Technologies, Inc. (IRTC) – Transaction d’initié Formulaire 4

Le 23 juin 2025, le Chief Commercial Officer Chad Patterson a vendu 936 actions ordinaires d’IRTC à 150,00 $ par action, générant un produit brut d’environ 140 400 $. La vente a été réalisée conformément à un plan de négociation Rule 10b5-1 adopté par Patterson le 25 novembre 2024, ce qui indique que la transaction était préprogrammée et pas nécessairement le résultat du sentiment du marché au moment.

Après la vente, Patterson détient 48 929 actions, conservant ainsi une participation importante dans la société. Aucun titre dérivé n’a été exercé ou cédé, et aucune autre transaction n’a été divulguée dans le Tableau II.

  • La vente représente environ 1,9 % des avoirs déclarés de Patterson, suggérant un rééquilibrage modéré du portefeuille plutôt qu’une réduction majeure.
  • L’utilisation d’un plan 10b5-1 améliore la transparence et atténue les inquiétudes concernant des opérations opportunistes.

iRhythm Technologies, Inc. (IRTC) – Insider-Transaktion Formular 4

Am 23. Juni 2025 verkaufte der Chief Commercial Officer Chad Patterson 936 Aktien der IRTC-Stammaktien zu je 150,00 $ und erzielte dadurch Bruttoerlöse von etwa 140.400 $. Der Verkauf erfolgte im Rahmen eines Rule 10b5-1 Handelsplans, den Patterson am 25. November 2024 eingeführt hatte, was darauf hinweist, dass die Transaktion vorab geplant war und nicht unbedingt auf aktuelle Marktstimmungen zurückzuführen ist.

Nach dem Verkauf hält Patterson weiterhin 48.929 Aktien und behält somit eine bedeutende Beteiligung am Unternehmen. Es wurden keine derivativen Wertpapiere ausgeübt oder veräußert, und es wurden keine weiteren Transaktionen in Tabelle II offengelegt.

  • Der Verkauf entspricht etwa 1,9 % von Pattersons gemeldeten Beständen und deutet eher auf eine moderate Portfolioanpassung als auf eine wesentliche Reduzierung hin.
  • Die Nutzung eines 10b5-1-Plans erhöht die Transparenz und verringert Bedenken hinsichtlich opportunistischer Handelsaktivitäten.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Roberts Johanna

(Last) (First) (Middle)
ONE PENUMBRA PLACE

(Street)
ALAMEDA CA 94502

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Penumbra Inc [ PEN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP, Gen. Counsel & Secretary
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/01/2025 S(1) 8 D $247.61(2) 66,649(3) D
Common Stock 07/01/2025 S(1) 2 D $249.27(4) 66,647(3) D
Common Stock 07/01/2025 S(1) 7 D $249.91(5) 66,640(3) D
Common Stock 07/01/2025 S(1) 81 D $251.16(6) 66,559(3) D
Common Stock 07/01/2025 S(1) 270 D $251.84(7) 66,289(3) D
Common Stock 07/01/2025 S(1) 46 D $252.87(8) 66,243(3) D
Common Stock 07/01/2025 S(1) 31 D $253.84(9) 66,212(3) D
Common Stock 07/01/2025 S(1) 93 D $254.8(10) 66,119(3) D
Common Stock 07/01/2025 S(1) 62 D $255.72(11) 66,057(3) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The sales were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
2. This transaction was executed in multiple trades at prices ranging from $247.37 to $248.05. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the SEC staff, the Issuer or a security holder of the Issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
3. A portion of these shares is subject to vesting.
4. This transaction was executed in multiple trades at prices ranging from $249.24 to $249.29. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the SEC staff, the Issuer or a security holder of the Issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
5. This transaction was executed in multiple trades at prices ranging from $249.54 to $250.36. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the SEC staff, the Issuer or a security holder of the Issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
6. This transaction was executed in multiple trades at prices ranging from $250.61 to $251.33. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the SEC staff, the Issuer or a security holder of the Issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
7. This transaction was executed in multiple trades at prices ranging from $251.38 to $252.35. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the SEC staff, the Issuer or a security holder of the Issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
8. This transaction was executed in multiple trades at prices ranging from $252.43 to $253.36. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the SEC staff, the Issuer or a security holder of the Issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
9. This transaction was executed in multiple trades at prices ranging from $253.40 to $254.28. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the SEC staff, the Issuer or a security holder of the Issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
10. This transaction was executed in multiple trades at prices ranging from $254.37 to $255.36. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the SEC staff, the Issuer or a security holder of the Issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
11. This transaction was executed in multiple trades at prices ranging from $255.37 to $256.08. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the SEC staff, the Issuer or a security holder of the Issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
Remarks:
/s/ Johanna Roberts 07/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many IRTC shares did Chad Patterson sell?

He sold 936 shares on 23 June 2025.

At what price were the IRTC shares sold?

The shares were sold at $150.00 per share.

How many IRTC shares does Patterson own after the sale?

He beneficially owns 48,929 shares following the transaction.

Was the sale part of a Rule 10b5-1 trading plan?

Yes. The transaction was executed under a Rule 10b5-1 plan adopted on 25 Nov 2024.

Does this insider sale materially impact iRhythm Technologies?

Given the small size (≈1.9 % of holdings) and pre-planned nature, the filing is considered neutral in impact.
Penumbra Inc

NYSE:PEN

PEN Rankings

PEN Latest News

PEN Latest SEC Filings

PEN Stock Data

9.82B
37.34M
3.93%
92.35%
3.52%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
ALAMEDA